Clinical trials
Immunity clinical trials
Below are recruiting immunity clinical trials, each written for real people, not researchers. We’re tracking 1,062 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06088732RecruitingPhase 1/Phase 2
Exercise and ibuprofen for bipolar depression
This study tests whether acute exercise and ibuprofen can improve symptoms of bipolar depression by studying their effects on the immune system and brain circuits. It may help if you are currently in a depressive episode and can do moderate physical activity.
Tulsa, OklahomaAges 18–55 - NCT06092463Recruiting
Immune system study in newborn intestines
This study looks at how the immune system develops in the intestines of newborns, including those born early or with a blocked intestine (atresia). It may help doctors understand inflammation and improve care for sick babies.
CopenhagenAges Up to 1 year - NCT06107608Recruiting
Scan for tumors in lung cancer patients on immunotherapy
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
BrusselsAges 18 years+ - NCT06109337Recruiting
Immune cells in children with ADHD
This study looks at immune system cells in the blood of children with ADHD. It aims to understand how these cells might be different, which could lead to new treatment ideas.
Hangzhou, ZhejiangAges 6–12 - NCT06116032Recruiting
Immune profiling for cancer immunotherapy response
This trial studies immune system changes in cancer patients receiving immunotherapy, such as checkpoint inhibitors or cell therapies. It aims to understand why some people respond better than others.
Lebanon, New HampshireAges 18 years+ - NCT06154252RecruitingPhase 2/Phase 3
Study of CABA-201 for active myositis in adults and children
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Orange, CaliforniaAges 6–75 - NCT06154668Recruiting
Immune cell study in melanoma patients
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
GrenobleAges 18 years+ - NCT06161285Recruiting
Gut germs and immune response in infant bronchiolitis
This study looks at how the germs in a baby's gut and their immune system respond to bronchiolitis (a common lung infection). If your baby is under 12 months and gets bronchiolitis during the RSV season, their participation could help us understand why some babies get very sick and others don't.
ClamartAges 1 day–1 year - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT06180993Recruiting
Nirsevimab for infants born in Galicia
This trial tests a preventive medicine called nirsevimab given to infants to see how well it protects them from a common serious lung infection. It is offered as part of regular check-ups for babies born during a specific time period.
Santiago de Compostela, A CoruñaAges 1 day–2 years - NCT06197581Recruiting
Safety of Radiation with Modern Breast Cancer Drugs
This study checks if giving certain modern breast cancer drugs at the same time as radiation is safe. It's for women who need radiation and are also taking one of these drugs: capecitabine, a CDK4/6 inhibitor, a PARP inhibitor, immunotherapy, or a HER2 inhibitor.
Beijing, Beijing MunicipalityAges 18–70 - NCT06199713Recruiting
Melanoma trial tracking treatment response with PET scans and blood tests
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
Madison, WisconsinAges 18 years+ - NCT06208826RecruitingPhase 2
Immunotherapy maintenance after surgery for head and neck cancer
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT06209723Recruiting
Vegetarian diet study for recent heart attack patients and their partners
This study tests whether a vegetarian diet can help the immune system recover after a heart attack. It is for people who recently had a heart attack and their healthy partners.
NijmegenAges 18 years+ - NCT06211868Recruiting
Early heart disease risk study for adults 40-70
This study looks at whether changing your immune system, fats, and metabolism can lower your risk of early heart disease. It is for people with an intermediate to high risk score but who have not yet had a heart attack or stroke.
SingaporeAges 40–70 - NCT06218303RecruitingPhase 1
Vaccine for early breast cancer (DCIS)
This trial tests a vaccine that targets a protein (MUC1) found in early breast cancer cells. It's for women with ER+ DCIS who are planning surgery, to see if the vaccine can help prevent the cancer from coming back or getting worse.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Ho Chi Minh City, Hồ Chí MinhAges 18–80 - NCT06248957Recruiting
Immune system study for people with hard-to-treat immune diseases
This study aims to understand the immune system in people who have immune problems or whose immune-related diseases are not helped by standard treatments. It may lead to better ways to diagnose and treat these conditions.
StockholmAges Any age - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06255223RecruitingPhase 2
Radiation therapy plus immunotherapy for advanced kidney cancer
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
Nanjing, JiangsuAges 18–80 - NCT06271252RecruitingPhase 1
Study of OriCAR-017 for relapsed or refractory multiple myeloma
This trial tests a new type of CAR-T cell therapy called OriCAR-017 for people with multiple myeloma that has come back or not responded to treatment. It is for patients who have already tried several treatments, including ones that target BCMA, and their last treatment stopped working.
Atlanta, GeorgiaAges 18–75 - NCT06278337Recruiting
Moesin-associated immunodeficiency study
This study looks at a rare immune system condition caused by changes in the MOESIN gene. It aims to better understand the condition and may help develop future treatments.
Bethesda, MarylandAges 4–80 - NCT06278857RecruitingPhase 2
Dostarlimab for early-stage MMR deficient endometrial cancer
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Sydney, New South WalesAges 18 years+ - NCT06279572Recruiting
Immune study of azacitidine and venetoclax in first AML treatment
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Scottsdale, ArizonaAges 18 years+
Hear when a new Immunity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunity?
- Yes. Clin2 currently lists 1,062 recruiting immunity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.